Non-small cell lung cancer, HER2-mutated
Revision as of 00:49, 20 January 2022 by Jwarner (talk | contribs) (Created page with "{{#lst:Section editor transclusions|nsclc}} Note: these are regimens tested in biomarker-specific populations, please see the '''main NSCLC page...")
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
4 variants on this page
|
Metastatic disease, all lines of therapy
Trastuzumab deruxtecan monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Li et al. 2021 (DESTINY-Lung01) | 2018-2020 | Phase 2 |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 6.4 mg/kg IV once on day 1
21-day cycles
References
- DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2021 Sep 18. Epub ahead of print. link to original article contains verified protocol PubMed NCT03505710